RxDoctor Payments DataLook up a doctor →

Hugo Ferrara, MD

Obstetrics & Gynecology · Hialeah, FLNPI 1629135330

Payments from drug & device makers

$408,907in general payments, 2019–2025

Across 410 payments — averaging $997.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$160K
  • Myovant Sciences GmbH$101K
  • Mitsubishi Tanabe Pharma Development America, Inc.$100K
  • Bayer$24K
  • Duchesnay USA Incorporated$16K
  • Myovant Sciences Inc.$3K
  • plus $5K from 28 others

What the payments were for

  • Food & beverage$4,62595%
  • Education$2415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$408,907 in reported general payments places this provider in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

See all obstetrics & gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$14,418
Medicare patients
46
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated125$55,949
MyrbetriqMirabegron94$49,340
GemtesaVibegron13$10,979
Estradiol129$6,953
Acyclovir31$3,735
Metronidazole67$3,005
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip79$1,409
ValacyclovirValacyclovir Hcl61$1,311
Terconazole34$753
ProgesteroneProgesterone, Micronized22$424
Fluconazole52$258
Oxybutynin Chloride32$257
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$242
Mupirocin14$107
Ibuprofen54$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$250$55,949125 claims
Astellas Pharma US IncMyrbetriq$588$49,34094 claims
Sumitomo Pharma America, Inc.Gemtesa$159,919$10,97913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.

Other obstetrics & gynecology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →